

euromed

Investor Presentation April 2020

forward looking statement

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Investor Presentation April 2020

euromed

EuroMED is an innovative European focused medical cannabis and hemp company with international production and distribution across the continent of Europe.



company overview

EuroMED is committed to becoming a leading manufacturer and distributor of premier medical cannabis and cannabinoid products across Europe through extraction, processing, marketing, distribution, and cultivation.

Switzerland: Genetics, cultivation, extraction, processing, and distribution of whole flower and derivative CBD products.

EU: Import and distribution of whole flower medical cannabis through EU pharmacies.

Israel: Cultivator and producer of medical grade cannabis.

strategic european footprint

Total production area of
nearly 500,000 sqft

	Switzerland	Germany	Israel
Type of Operations	Hemp/CBD	Medical Cannabis	Medical Cannabis
Phase 1 Capacity	100.000 sqft	20.000	44.000 sqft
Max Capacity	200.000 sqft	20.000	270.000 sqft



North American market is crowded,
however Europe is primed for growth.

The organic CBD market in Europe is a unique opportunity: demand has outstripped supply, and the market has carefully controlled access to production and distribution.

It is the European Green Rush.

790
million

A population more than double that of the US and Canada combined, Europe is set to become the world's largest legal cannabis market over the next 5 years.

In 2020
and beyond


Europe can expect to see progress towards a single-market distribution programme for cannabis-based medicinal products.

positioning

\$39B

European market opportunity

Well positioned for Europe
EuroMED has established ground presence with seasoned cannabis operators in Switzerland, Germany, EU, and Israel to capture the \$39B European market opportunity.



3x

increase yield by

eu gmp
certificationcbd
establish partnershipsb2b2c
premium medical grade**Expand production capacity via acquisitions and supply off take agreements**

- Buildout medical cannabis production and expand hemp cultivation facilities in Switzerland to increase yield by 3x
- Grow through strategically sourced accretive acquisitions

Streamline operations

- Secure EU GMP certification in the EU and establish CBD products within Novel Food regulations.
- Increase intercompany cross border flower exports & expand CBD product presence beyond Switzerland into Germany, France, Italy, UK, Spain, Poland, Denmark and Czech Republic

Activate additional channels of distribution in Europe

- Add pharmacy distribution networks and drug distributors in the German medical market
- Increase retail awareness of CBD products in Switzerland
- Establish partnerships with European CBD distributors

Develop iconic brand portfolio

- Made in Switzerland CBD brand (B2C)
- Research backed cannabis & hemp genetics (B2B)
- Premium medical grade cannabis (B2B2C)

We aspire to emerge as the leading European innovator

Switzerland Research

Cannabinoids and Terpenes research and development
Seed genetic research & proprietary strain development

- Headed by leading tissue engineering & stem cell researcher
- Purpose specific strain development
- Superior yields/ accelerated growth cycles

Canalytics Medical grade extraction

Licensed medical cannabis research

- Extraction of pharmaceutical high – grade CBD oils

Synthetics and semi-synthetics creations

Patenting of new innovations and certifications of new strains

FutureMed Clinics

Import and distribution operations to service medical cannabis
Market and certified Clinics

- Import/Export
- Distribute
- Sell & market direct to big pharma and through pharmacy networks, in UK and the EU

euromed canalytics ag

Dr. Thomas Sebastian Vetter has entered into a landmark research partnership with EuroMED to extract and produce cultured cannabinoids at scale.

- Using biosynthesis as the means of production, will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare
- EuroMED/Canalytics is commercializing key patented intellectual property related to the production of the target cannabinoids perpetually and globally.



rollout plan

Phase 1A
Q2-3 2020

Move current laboratory and DNA research center in Zurich to EuroMed/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland. The 1,000 sqm facility will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Budget \$2.5M

Phase 1B
Q2-3 2020

Expand/relocate current cultivation facilities to St Gallen 1,000+ sqm. Budget \$1M



Phase 2
Q2-3 2020

Build 1st phase (in Israel) of 22,000 sqft of a total of 270,000 sqft, commercial scale GMP & GAP medical cannabis cultivation & manufacturing facility. Initial budget \$2.0M



Phase 3
Q1 2021

Expand St Gallen cultivation facility, to 2nd floor, 2,200 sqm. Budget \$1.5M



extraction centre

EuroMED/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland. The facility will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Construction of the new Extraction Centre is expected to begin in 30-45 days and the facility is scheduled to release its first concentrates by the beginning of Q3.

The Extraction Centre will give EuroMED/Canalytics a significant competitive advantage in cannabis concentrates, which are expected to be a significant product category. This is the latest example of our continued leadership in cannabis product innovation. EuroMED/Canalytics will further its expertise delivering unparalleled innovative products to meet the medical and consumer demand. This facility will be the centre of industry-leading R&D and commercial production of next generation cannabis concentrate products.

200,00 kgs
of cannabis annually

The custom designed facility will house Class 1/Division 1 extraction rooms as well as production, packaging facilities and will have the capacity to process in excess of 200,000 kgs of cannabis annually.



clinical distribution partnership

FUTUREMED CLINIC ZURICH

Located at the heart of Zurich, FurtureMed is a private multidisciplinary medical centre that provides medical cannabis derivative products through certified affiliated clinics throughout the EU.

FurtureMed strives to offer quality medical CBD/THC, procured by a team of cannabis specialists using the latest medical methods and technology.

FurtureMed's affiliate clinics offer a spacious and pleasant environment. The well-being of their patients is an essential component.



medical cannabis production facilities in israel

EuroMED has obtained preliminary licenses to establish nursery, cultivation, manufacturing and distribution operations and is in the process of constructing a custom-built greenhouse and manufacturing facility for cannabis.

Building distribution relationships into Germany and other European countries for medical flower.

Phase I: Constructing 22,000 sqft modular greenhouse.

Design allows for an addition of 11,000 sqft greenhouse module every 35 days.

Maximum yield output of 67,500,000 grams of medical flower at full capacity.

Expected annual yield of 5,500 kg of flower

management bios

Patrick Morris CEO, Director

Patrick Morris is an entrepreneur and capital market executive with over 15 years of experience, raising funds for microcap companies in a number of industries, including pharmaceutical cannabis, resource exploration, blockchain technologies and finance. In addition, Mr. Morris co-created and co-produced Canada's first nationally syndicated radio show about growth stock opportunities, which was broadcast on 14 of the top-rated news talk stations across Canada. Prior to the capital markets Patrick also has 5 years of experience in wine and spirits importing, sales and portfolio management.

Dr David Dalton Director

With a rich history in pharmaceutical retail and health resources, Dr. David Dalton brings a wide range of expertise across a number of categories. Formerly serving as Executive Vice President at Rite Aid and Senior Vice President of Peoples Drug Stores, Dr. Dalton also launched Health Resources Inc, the first African American pharmaceutical company in the USA. Dr. Dalton was named as one of the top 100 Leaders in Healthcare and has received the Medal of Freedom. He is a member of the Black CEO Hall of Fame.

Geoff Balderson CFO, Director

Deeply involved in the public company sector for 25 years, Geoff Balderson brings a wealth of experience in the management of both public and private companies. His work in listing a number of CPCs on public markets speaks to his experience and tenure over the past two and a half decades. Geoff's guidance is a key component to the current and future success of each facet of EuroMED.

management bios

Dr. Med. PhD. Thomas Sebastian Vette
 Managing Director & Chief Scientist, Canalytics AG, Zurich.

Dr. Vette is Managing Director and Chief Scientist, Canalytics AG, Zurich. Canalytics AG, main activities are in the field of cannabis research and development, specifically genetical research and development of new cannabis strains. He is president of the board of directors, Stem Cell Bank of Switzerland, Zurich. He also is clinic director and leading physician of Futuremed Clinic Zurich planning and development of a new holistic concept based on a private clinic setup, including clinical services of different medical disciplines with an integrated research facility, laboratory, surgical theatres and intermediate care infrastructure, all within a fully integrated teaching environment.

Tanner Saner
 Director of Swiss Operations

Tanner has been instrumental in providing the seed capital to start the two cultivation facilities in Staad and Herisau, assembled the cultivation team and marketing and sales of SperoPharma's products. He also communicates on behalf of the company with government entities and the public. He leads the development of the company's short-and long term Cannabis strategy, creates and implementing the company's vision and mission. He provides EuroMED with market awareness of the competitive market landscape, expansion opportunities, and industrial developments. He also ensures that the company maintains high social responsibility where it does business.

Dusan Cecavac
 Master Grower

Dusan oversees operations at SperoPharma's two cannabis production facilities, in Staad and Herisau. His focus includes sourcing, cloning, transplanting, and providing nutrients for various strains of marijuana plants; setting up and maintaining irrigation systems and environmental controls; and ensuring that the facility is pest-free. Dusan also manages other cannabis production employees, including cultivation technicians, bud trimmers and keeps track of SperoPharma's two facilities inventory.

management bios

Chris Farnworth

Managing Director & Business Development EU

A business management and corporate finance executive, Chris has over 35 years of experience in the public and private markets. He brings extensive worldwide high-level business development and financing structure experience, specifically in Europe, MENA and Asia along with sales and operational experience with large and small multi-national public companies focusing on business development, project management, strategic planning and partnership development.



Israel Moseson

COO of IsraCann Biosciences

Involvement within the Israeli cannabis space for over 5 years with strong governmental ties.

Mark Zegal

Strategic Advisor for IsraCann Biosciences

Extensive experience in US Public Markets for past 25 years.


Dr. Dvir Teler

Ph.D., Plant Molecular Biology & Phytopathology

Extensive experience in consulting, growing and plant research.

comparables

Company	Exchange	Share Price	Market CAP (million)
Sativa Group	NEX	\$4.68	\$28.14
World High Life	NEX	\$15	\$23
Zoetic Int.	LSE	\$6.85	\$13
Spinnaker Plc	LSE	\$6.10	\$6.10
Adanda Dev Plc	NEX	\$.31	\$1.3
Freyherr Plc	NEX	\$127.40	\$32.8
GW Pharma	NASDAQ	\$100	\$3,075
EuroMed	TBA	\$.30 (US\$.21)	Est. \$24



investment terms

Amount:

CND 1,000,000+ (675,000 CHF)

Price:

CND 0.15 (.10 CHF)

2 Year Warrant:

CND 0.30 (.21 CHF)

IPO:

\$10M+ at \$0.40 (.27 CHF)



Contact

Patrick Morris CEO, Director

M: 604.761.8597

E: pm@euromedtherapeutics.com

Skype: pctmorris

Vancouver, Jerusalem, Zurich

euromed

euromedtherapeutics.com

Contact

Chris Farnworth. Managing Director
and Business Development EU

M: +1.604.250.1060

Zurich: +41.79.967.56.21

E: chris@euromedtherapeutics.com

Skype: duncanhelsh

Zurich, Vancouver, London

